<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="7885b2a8-be4e-48ab-8113-4e6ab791eb98"><labelDrug name="Avapro"><Normalization><mmtx cui="C0595301" preferredWord="Avapro" semType="phsu, orch"/></Normalization></labelDrug><generic name="irbesartan"/><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.1" text="Drug Label for drug brand Avapro, containing irbesartan." type="negative"><entity charOffset="26:32" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.1.e.0" text="avapro" type="Biomedical_Entity"><Normalization><mmtx cui="C0595301" phraseText="Drug Label for drug brand Avapro," preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><entity charOffset="0:19" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.1.e.1" text="drug drug" type="Biomedical_Entity"><Normalization><mmtx cui="C0013231" phraseText="Drug Label for drug brand Avapro," preferredWord="Drugs, Non-Prescription" semType="phsu"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="45:55" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.1.e.2" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="irbesartan." preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.1.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.1.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.1.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.1.e.2"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.1.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.1.e.2"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.7" text="AVAPRO (irbesartan) is an angiotensin II receptor (AT1 subtype) antagonist." type="negative"><entity charOffset="8:18" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.7.e.0" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="(irbesartan" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><entity charOffset="0:6" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.7.e.1" text="avapro" type="Biomedical_Entity"><Normalization><mmtx cui="C0595301" phraseText="AVAPRO" preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><entity charOffset="26:40" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.7.e.2" text="angiotensin ii" type="Biomedical_Entity"><Normalization><mmtx cui="C0003009" phraseText="an angiotensin II receptor" preferredWord="Angiotensin II" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.7.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.7.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.7.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.7.e.2"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.7.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.7.e.2"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.12" text="Irbesartan is slightly soluble in alcohol and methylene chloride and practically insoluble in water." type="negative"><entity charOffset="46:64" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.12.e.0" text="methylene chloride" type="Biomedical_Entity"><Normalization><mmtx cui="C0025748" phraseText="methylene chloride" preferredWord="methylene chloride" semType="phsu, orch, hops"/><RxNorm RxCui="1311537"/></Normalization></entity><entity charOffset="0:10" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.12.e.1" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="Irbesartan" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.12.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.12.e.0"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.13" text="AVAPRO is available for oral administration in unscored tablets containing 75 mg, 150 mg, or 300 mg of irbesartan. " type="negative"><entity charOffset="0:6" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.13.e.0" text="avapro" type="Biomedical_Entity"><Normalization><mmtx cui="C0595301" phraseText="AVAPRO" preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><entity charOffset="93:113" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.13.e.1" text="300 mg irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0986850" phraseText="300 mg of irbesartan." preferredWord="irbesartan 300 MG" semType="clnd"/><RxNorm RxCui="NA"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.13.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.13.e.1"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14" text="Inactive ingredients include: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hypromellose, silicon dioxide, magnesium stearate, titanium dioxide, and polyethylene glycol 3000." type="negative"><entity charOffset="175:199" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.0" text="polyethylene glycol 3000" type="Biomedical_Entity"><Normalization><mmtx cui="C3256556" phraseText="polyethylene glycol 3000." preferredWord="POLYETHYLENE GLYCOL 3000" semType="phsu, orch"/><RxNorm RxCui="54961"/></Normalization></entity><entity charOffset="79:100" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.1" text="croscarmellose sodium" type="Biomedical_Entity"><Normalization><mmtx cui="C0010353" phraseText="croscarmellose sodium," preferredWord="Croscarmellose Sodium" semType="phsu, carb"/><RxNorm RxCui="1310574"/></Normalization></entity><entity charOffset="51:77" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.2" text="microcrystalline cellulose" type="Biomedical_Entity"><Normalization><mmtx cui="C0669247" phraseText="microcrystalline cellulose," preferredWord="microcrystalline cellulose" semType="phsu, carb, bodm"/><RxNorm RxCui="1239123"/></Normalization></entity><entity charOffset="30:49" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.3" text="lactose monohydrate" type="Biomedical_Entity"><Normalization><mmtx cui="C1658042" phraseText="lactose monohydrate," preferredWord="Lactose Monohydrate" semType="phsu, orch"/><RxNorm RxCui="6211"/></Normalization></entity><entity charOffset="153:169" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.4" text="titanium dioxide" type="Biomedical_Entity"><Normalization><mmtx cui="C0076733" phraseText="titanium dioxide," preferredWord="titanium dioxide" semType="inch, phsu"/><RxNorm RxCui="1305547"/></Normalization></entity><entity charOffset="133:151" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.5" text="magnesium stearate" type="Biomedical_Entity"><Normalization><mmtx cui="C0126791" phraseText="magnesium stearate," preferredWord="Magnesium stearate" semType="phsu, lipd"/><RxNorm RxCui="6574"/></Normalization></entity><entity charOffset="116:131" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.6" text="silicon dioxide" type="Biomedical_Entity"><Normalization><mmtx cui="C0885771" phraseText="silicon dioxide," preferredWord="Silicea terra homeopathic preparation" semType="phsu"/><RxNorm RxCui="9774"/></Normalization></entity><entity charOffset="102:114" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.7" text="hypromellose" type="Biomedical_Entity"><Normalization><mmtx cui="C0063242" phraseText="hypromellose," preferredWord="hypromellose" semType="phsu, carb"/><RxNorm RxCui="27334"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.3" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.4" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.5" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.6" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.7" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.3" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.4"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.5"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.6"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.7"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.3" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.2"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.4"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.5"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.6"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.7"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.3" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.4"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.3" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.5"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.3" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.6"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.3" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.7"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.5" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.4"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.6" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.4"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.7" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.4"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.6" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.5"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.7" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.5"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.7" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.14.e.6"/></sentence><sentence biomedicalEntities="2" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18" lineNumber="26" text="Do not coadminister aliskiren with AVAPRO in patients with diabetes (see PRECAUTIONS: Drug Interactions )." type="regular"><entity charOffset="0:19" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.e.0" text="Do not coadminister" type="Caution_Interaction"/><entity charOffset="20:29" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.e.2" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren with AVAPRO" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="35:41" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.e.3" text="AVAPRO" type="Drug"><Normalization><mmtx cui="C0595301" phraseText="aliskiren with AVAPRO" preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><entity charOffset="59:67" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.e.4" text="diabetes" type="SPAN"><Normalization><mmtx cui="C0011847" phraseText="with diabetes" preferredWord="Diabetes" semType="dsyn"/><mmtx cui="C0011849" phraseText="with diabetes" preferredWord="Diabetes Mellitus" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.ddi.1"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.e.0"><relations><relation type="hasContext"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.e.2"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.e.4" ddi="true" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.e.3" trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.18.e.0" type="Caution_Interaction"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.25" text="Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. " type="negative"><entity charOffset="168:179" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.25.e.0" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="the renin-angiotensin system from other antihypertensive agents." preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="75:91" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.25.e.1" text="antihypertensive" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="to antihypertensive use" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><entity charOffset="198:221" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.25.e.2" text="antihypertensive agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="the renin-angiotensin system from other antihypertensive agents." preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.25.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.25.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.25.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.25.e.2"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.33" text="When pregnant rats were treated with irbesartan from day 0 to day 20 of gestation (oral doses of 50 mg/kg/day, 180 mg/kg/day, and 650 mg/kg/day), increased incidences of renal pelvic cavitation, hydroureter and/or absence of renal papilla were observed in fetuses at doses 50 mg/kg/day (approximately equivalent to the maximum recommended human dose MRHD, 300 mg/day, on a body surface area basis). " type="negative"><entity charOffset="391:396" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.33.e.0" text="basis" type="Biomedical_Entity"><Normalization><mmtx cui="C1874451" phraseText="on a body surface area basis" preferredWord="Basis" semType="phsu"/><RxNorm RxCui="1046801"/></Normalization></entity><entity charOffset="37:47" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.33.e.1" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="treated with irbesartan" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.33.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.33.e.0"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.37" text="Surviving females receiving this dose (about 1.5 times the MRHD on a body surface area basis) had a slight increase in early resorptions and a corresponding decrease in live fetuses. " type="negative"><entity charOffset="0:9" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.37.e.0" text="surviving" type="Biomedical_Entity"><Normalization><mmtx cui="C0310255" phraseText="Surviving females" preferredWord="SURVIVE" semType="phsu"/><RxNorm RxCui="9671"/></Normalization></entity><entity charOffset="87:92" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.37.e.1" text="basis" type="Biomedical_Entity"><Normalization><mmtx cui="C1874451" phraseText="the MRHD on a body surface area basis" preferredWord="Basis" semType="phsu"/><RxNorm RxCui="1046801"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.37.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.37.e.1"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.41" text="Initiation of antihypertensive therapy may cause symptomatic hypotension in patients with intravascular volume- or sodium-depletion, eg, in patients treated vigorously with diuretics or in patients on dialysis. " type="negative"><entity charOffset="14:30" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.41.e.0" text="antihypertensive" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="Initiation of antihypertensive therapy" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><entity charOffset="115:121" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.41.e.1" text="sodium" type="Biomedical_Entity"><Normalization><mmtx cui="C0597484" phraseText="sodium-depletion," preferredWord="Sodium Cation" semType="phsu, elii"/><RxNorm RxCui="1444874"/></Normalization></entity><entity charOffset="173:182" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.41.e.2" text="diuretics" type="Biomedical_Entity"><Normalization><mmtx cui="C0012798" phraseText="vigorously with diuretics" preferredWord="Diuretics" semType="phsu"/><RxNorm RxCui="3567"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.41.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.41.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.41.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.41.e.2"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.41.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.41.e.2"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.46" text="As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. " type="negative"><entity charOffset="53:64" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.46.e.0" text="aldosterone" type="Biomedical_Entity"><Normalization><mmtx cui="C0002006" phraseText="the renin-angiotensin-aldosterone system," preferredWord="Aldosterone" semType="strd, phsu, horm"/><RxNorm RxCui="1312358"/></Normalization></entity><entity charOffset="41:52" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.46.e.1" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="the renin-angiotensin-aldosterone system," preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.46.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.46.e.0"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.47" text="In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (eg, patients with severe congestive heart failure), treatment with angiotensin-converting-enzyme inhibitors has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. " type="negative"><entity charOffset="85:96" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.47.e.0" text="aldosterone" type="Biomedical_Entity"><Normalization><mmtx cui="C0002006" phraseText="depend on the activity of the renin-angiotensin-aldosterone system" preferredWord="Aldosterone" semType="strd, phsu, horm"/><RxNorm RxCui="1312358"/></Normalization></entity><entity charOffset="73:84" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.47.e.1" text="angiotensin" type="Biomedical_Entity"><Normalization><mmtx cui="C0003018" phraseText="depend on the activity of the renin-angiotensin-aldosterone system" preferredWord="Angiotensins" semType="bacs, phsu, aapp"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="172:212" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.47.e.2" text="angiotensin-converting-enzyme inhibitors" type="Biomedical_Entity"><Normalization><mmtx cui="C0003015" phraseText="treatment with angiotensin-converting-enzyme inhibitors" preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="6162"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.47.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.47.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.47.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.47.e.2"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.47.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.47.e.2"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54" text="No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, and nifedipine." type="negative"><entity charOffset="163:173" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.0" text="nifedipine" type="Biomedical_Entity"><Normalization><mmtx cui="C0028066" phraseText="nifedipine." preferredWord="Nifedipine" semType="phsu, orch"/><RxNorm RxCui="7417"/></Normalization></entity><entity charOffset="140:147" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.1" text="digoxin" type="Biomedical_Entity"><Normalization><mmtx cui="C0012265" phraseText="digoxin," preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><entity charOffset="119:138" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.2" text="hydrochlorothiazide" type="Biomedical_Entity"><Normalization><mmtx cui="C0020261" phraseText="studies with hydrochlorothiazide," preferredWord="Hydrochlorothiazide" semType="phsu, orch"/><RxNorm RxCui="5487"/></Normalization></entity><entity charOffset="149:157" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.3" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="warfarin," preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.3" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.3"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.54.e.3"/></sentence><sentence biomedicalEntities="5" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55" lineNumber="43" text="In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, tolbutamide and nifedipine. " type="regular"><entity charOffset="0:16" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.0" text="In vitro studies" type="SPAN"/><entity charOffset="22:73|85:96" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.1" text="significant inhibition of the formation of oxidized metabolites" type="Specific_Interaction"/><entity charOffset="112:152" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.3" text="cytochrome CYP 2C9 substrates/inhibitors" type="Drug_Class"><Normalization><RxNorm RxCui="3065"/></Normalization></entity><entity charOffset="153:165" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.4" text="sulphenazole" type="Drug"><Normalization><RxNorm RxCui="56798"/></Normalization></entity><entity charOffset="167:178" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.5" text="tolbutamide" type="Drug"><Normalization><mmtx cui="C0040374" phraseText="tolbutamide" preferredWord="Tolbutamide" semType="phsu, orch"/><RxNorm RxCui="10635"/></Normalization></entity><entity charOffset="183:193" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.6" text="nifedipine" type="Drug"><Normalization><mmtx cui="C0028066" phraseText="nifedipine." preferredWord="Nifedipine" semType="phsu, orch"/><RxNorm RxCui="7417"/></Normalization></entity><entity charOffset="74:84" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.10" text="irbesartan" type="Drug"><Normalization><mmtx cui="C0288171" phraseText="significant inhibition of the formation of oxidized irbesartan metabolites" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><drugClassMembership drug="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.4" drugClass="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.3"/><drugClassMembership drug="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.5" drugClass="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.3"/><drugClassMembership drug="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.6" drugClass="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.3"/><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.ddi.1"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.10"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.6"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.5"/></relation><relation type="hasEvidence"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.10" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.4" evidence="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.0" trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.1" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.10" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.6" evidence="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.0" trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.1" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.10" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.5" evidence="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.0" trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.1" type="Specific_Interaction"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.4" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.6"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.4" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.5"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.5" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.55.e.6"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.56" text="However, in clinical studies the consequences of concomitant irbesartan on the pharmacodynamics of warfarin were negligible. " type="negative"><entity charOffset="99:107" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.56.e.0" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="of warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="61:71" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.56.e.1" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="the consequences of concomitant irbesartan" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.56.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.56.e.0"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58" text="In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin. " type="negative"><entity charOffset="235:242" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.0" text="digoxin" type="Biomedical_Entity"><Normalization><mmtx cui="C0012265" phraseText="pharmacokinetics of digoxin." preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><entity charOffset="194:205" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.1" text="prothrombin" type="Biomedical_Entity"><Normalization><mmtx cui="C0033706" phraseText="(prothrombin time" preferredWord="Prothrombin" semType="bacs, phsu, aapp"/><RxNorm RxCui="1441688"/></Normalization></entity><entity charOffset="63:71" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.2" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="maintenance doses of warfarin," preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="184:192" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.3" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="no effect on the pharmacodynamics of warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="106:116" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.4" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="irbesartan administration for 7 days" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><entity charOffset="97:104" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.5" text="digoxin" type="Biomedical_Entity"><Normalization><mmtx cui="C0012265" phraseText="digoxin," preferredWord="Digoxin" semType="strd, phsu, carb"/><RxNorm RxCui="3407"/></Normalization></entity><entity charOffset="73:92" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.6" text="hydrochlorothiazide" type="Biomedical_Entity"><Normalization><mmtx cui="C0020261" phraseText="hydrochlorothiazide," preferredWord="Hydrochlorothiazide" semType="phsu, orch"/><RxNorm RxCui="5487"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.3" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.4" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.6" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.3" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.4" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.5" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.6" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.4"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.5"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.6"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.4" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.3"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.5" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.3"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.6" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.3"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.5" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.4"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.6" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.4"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.6" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.58.e.5"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.59" text="The pharmacokinetics of irbesartan were not affected by coadministration of nifedipine or hydrochlorothiazide." type="negative"><entity charOffset="90:109" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.59.e.0" text="hydrochlorothiazide" type="Biomedical_Entity"><Normalization><mmtx cui="C0020261" phraseText="hydrochlorothiazide." preferredWord="Hydrochlorothiazide" semType="phsu, orch"/><RxNorm RxCui="5487"/></Normalization></entity><entity charOffset="76:86" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.59.e.1" text="nifedipine" type="Biomedical_Entity"><Normalization><mmtx cui="C0028066" phraseText="affected by coadministration of nifedipine" preferredWord="Nifedipine" semType="phsu, orch"/><RxNorm RxCui="7417"/></Normalization></entity><entity charOffset="24:34" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.59.e.2" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="The pharmacokinetics of irbesartan" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.59.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.59.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.59.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.59.e.0"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.59.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.59.e.1"/></sentence><sentence biomedicalEntities="3" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60" lineNumber="45" text="Concomitant use of potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium." type="irregular"><entity charOffset="19:46" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.0" text="potassium-sparing diuretics" type="Drug_Class"><Normalization><mmtx cui="C0304490" phraseText="Concomitant use of potassium-sparing diuretics," preferredWord="Potassium Sparing Diuretics" semType="phsu"/><RxNorm RxCui="1437061"/></Normalization></entity><entity charOffset="48:69" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.1" text="potassium supplements" type="Drug_Class"><Normalization><mmtx cui="C0304475" phraseText="potassium supplements," preferredWord="Potassium supplement" semType="inch, phsu"/><RxNorm RxCui="8588"/></Normalization></entity><entity charOffset="74:111" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.2" text="salt substitutes containing potassium" type="Substance"><Normalization><mmtx cui="C0784217" phraseText="salt substitutes" preferredWord="Salt Substitute" semType="inch, phsu"/><mmtx cui="C0597277" phraseText="potassium" preferredWord="Potassium Ion" semType="phsu, elii"/><RxNorm RxCui="9547"/></Normalization></entity><entity charOffset="124:152" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.3" text="increases in serum potassium" type="Specific_Interaction"/><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.ddi.1"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.3"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.1"/></relation><relation type="hasObject"><labelDrug text="Avapro"/><normalization><mmtx><preferredWord>Avapro</preferredWord><phraseText>aliskiren with AVAPRO</phraseText><cuiCode>C0595301</cuiCode><semType>phsu</semType><semType>orch</semType></mmtx></normalization></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.2"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.0"/><pair ddi="true" e1="labelDrug" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.60.e.1"/></sentence><sentence biomedicalEntities="4" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61" lineNumber="46" text="In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including irbesartan, may result in deterioration of renal function, including possible acute renal failure. " type="regular"><entity charOffset="20:27" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.0" text="elderly" type="SPAN"/><entity charOffset="29:44" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.1" text="volume-depleted" type="SPAN"/><entity charOffset="92:118" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.2" text="compromised renal function" type="SPAN"/><entity charOffset="140:146" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.3" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="coadministration of NSAIDs," preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="158:184" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.4" text="selective COX-2 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1257954" phraseText="selective COX-2 inhibitors," preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="1431714"/></Normalization></entity><entity charOffset="191:226" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.5" text="angiotensin II receptor antagonists" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="with angiotensin II receptor antagonists," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="238:248" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.6" text="irbesartan" type="Drug"><Normalization><mmtx cui="C0288171" phraseText="irbesartan," preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><entity charOffset="264:295" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.7" text="deterioration of renal function" type="Specific_Interaction"/><entity charOffset="316:335" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.9" text="acute renal failure" type="Specific_Interaction"><Normalization><mmtx cui="C0022660" phraseText="possible acute renal failure." preferredWord="Kidney Failure, Acute" semType="dsyn"/></Normalization></entity><classClassMembership drugClass="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.4"/><drugClassMembership drug="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.6" drugClass="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.5"/><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.ddi.1"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.7"><relations><relation type="hasContext"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.0"/></relation><relation type="hasContext"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.3"/></relation><relation type="hasContext"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.5"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.ddi.2"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.9"><relations><relation type="hasContext"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.0"/></relation><relation type="hasContext"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.5"/></relation><relation type="hasContext"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.1"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.0, Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.2, Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.1" ddi="true" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.3" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.5" trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.61.e.7" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.63" lineNumber="46" text="Monitor renal function periodically in patients receiving irbesartan and NSAID therapy." type="regular"><entity charOffset="0:7" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.63.e.0" text="Monitor" type="Caution_Interaction"/><entity charOffset="58:68" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.63.e.2" text="irbesartan" type="Drug"><Normalization><mmtx cui="C0288171" phraseText="irbesartan" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><entity charOffset="73:78" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.63.e.3" text="NSAID" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="NSAID therapy." preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.63.ddi.1"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.63.e.0"><relations><relation type="hasObject"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.63.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.63.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.63.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.63.e.3" trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.63.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="4" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64" lineNumber="47" text="The antihypertensive effect of angiotensin II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors." type="regular"><entity charOffset="4:27|97:107" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.0" text="antihypertensive effect attenuated" type="Specific_Interaction"/><entity charOffset="31:66" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.2" text="angiotensin II receptor antagonists" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="The antihypertensive effect of angiotensin II receptor antagonists," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><RxNorm RxCui="839"/></Normalization></entity><entity charOffset="78:88" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.3" text="irbesartan" type="Drug"><Normalization><mmtx cui="C0288171" phraseText="irbesartan," preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><entity charOffset="111:117" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.5" text="NSAIDs" type="Drug_Class"><Normalization><mmtx cui="C0003211" phraseText="attenuated by NSAIDs" preferredWord="Anti-Inflammatory Agents, Non-Steroidal" semType="phsu"/><RxNorm RxCui="889"/></Normalization></entity><entity charOffset="128:154" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.6" text="selective COX-2 inhibitors" type="Drug_Class"><Normalization><mmtx cui="C1257954" phraseText="selective COX-2 inhibitors." preferredWord="Cyclooxygenase 2 Inhibitors" semType="phsu, orch"/><RxNorm RxCui="1431714"/></Normalization></entity><drugClassMembership drug="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.3" drugClass="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.2"/><classClassMembership drugClass="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.6"/><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.ddi.1"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.0"><relations><relation type="hasObject"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.5"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.5" trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.0" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65" lineNumber="48" text="Dual blockade of the RAS with angiotensin-receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. " type="irregular"><entity charOffset="30:59" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.0" text="angiotensin-receptor blockers" type="Drug_Class"><Normalization><mmtx cui="C0521942" phraseText="with angiotensin-receptor blockers," preferredWord="Angiotensin II receptor antagonist" semType="phsu"/><mmtx cui="C0815017" phraseText="with angiotensin-receptor blockers," preferredWord="Angiotensin Receptor Antagonists" semType="phsu"/><RxNorm RxCui="9164"/></Normalization></entity><entity charOffset="61:75" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.1" text="ACE inhibitors" type="Drug_Class"><Normalization><mmtx cui="C0003015" phraseText="ACE inhibitors," preferredWord="Angiotensin-Converting Enzyme Inhibitors" semType="phsu"/><RxNorm RxCui="221294"/></Normalization></entity><entity charOffset="80:89" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.2" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="128:139" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.3" text="hypotension" type="Specific_Interaction"/><entity charOffset="141:153" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.5" text="hyperkalemia" type="Specific_Interaction"/><entity charOffset="159:184" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.7" text="changes in renal function" type="Specific_Interaction"/><entity charOffset="196:215" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.9" text="acute renal failure" type="Specific_Interaction"><Normalization><mmtx cui="C0022660" phraseText="acute renal failure" preferredWord="Kidney Failure, Acute" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.ddi.1"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.3"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64" text="The antihypertensive effect of angiotensin II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors."><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.3"/></ellipsisSentence></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.ddi.2"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.5"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64" text="The antihypertensive effect of angiotensin II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors."><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.3"/></ellipsisSentence></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.ddi.3"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.7"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64" text="The antihypertensive effect of angiotensin II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors."><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.3"/></ellipsisSentence></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.ddi.4"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.9"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.0"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.2"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.1"/></relation><relation type="hasObject"><ellipsisSentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64" text="The antihypertensive effect of angiotensin II receptor antagonists, including irbesartan, may be attenuated by NSAIDs including selective COX-2 inhibitors."><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.64.e.3"/></ellipsisSentence></relation></relations></interaction></drugInteraction><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.2"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.0"/><pair ddi="true" e1="labelDrug" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.2"/><pair ddi="true" e1="labelDrug" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.65.e.1"/></sentence><sentence biomedicalEntities="2" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.66" lineNumber="48" text="Closely monitor blood pressure, renal function, and electrolytes in patients on AVAPRO and other agents that affect the RAS." type="regular"><entity charOffset="8:15" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.66.e.0" text="monitor" type="Caution_Interaction"/><entity charOffset="80:86" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.66.e.2" text="AVAPRO" type="Drug"><Normalization><mmtx cui="C0595301" phraseText="on AVAPRO" preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><entity charOffset="97:123" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.66.e.3" text="agents that affect the RAS" type="Drug_Class"><Normalization><mmtx cui="C1254351" phraseText="other agents" preferredWord="Pharmacologic Substance" semType="phsu"/><RxNorm RxCui="126263"/></Normalization></entity><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.66.ddi.1"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.66.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.66.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.66.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.66.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.66.e.3" trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.66.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67" lineNumber="49" text="Do not coadminister aliskiren with AVAPRO in patients with diabetes. " type="regular"><entity charOffset="0:19" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.e.0" text="Do not coadminister" type="Caution_Interaction"/><entity charOffset="20:29" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.e.2" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="aliskiren with AVAPRO" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="35:41" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.e.3" text="AVAPRO" type="Drug"><Normalization><mmtx cui="C0595301" phraseText="aliskiren with AVAPRO" preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><entity charOffset="59:67" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.e.4" text="diabetes" type="SPAN"><Normalization><mmtx cui="C0011847" phraseText="with diabetes." preferredWord="Diabetes" semType="dsyn"/><mmtx cui="C0011849" phraseText="with diabetes." preferredWord="Diabetes Mellitus" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.ddi.1"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.e.0"><relations><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.e.2"/></relation><relation type="hasObject"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.e.3"/></relation><relation type="hasContext"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.e.4"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.e.4" ddi="true" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.e.3" trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.67.e.0" type="Caution_Interaction"/></sentence><sentence biomedicalEntities="2" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68" lineNumber="49" text="Avoid use of aliskiren with AVAPRO in patients with renal impairment (GFR 60 mL/min)." type="regular"><entity charOffset="0:5" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.e.0" text="Avoid" type="Caution_Interaction"/><entity charOffset="13:22" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.e.2" text="aliskiren" type="Drug"><Normalization><mmtx cui="C1120110" phraseText="use of aliskiren" preferredWord="aliskiren" semType="phsu, orch"/><RxNorm RxCui="325646"/></Normalization></entity><entity charOffset="28:34" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.e.3" text="AVAPRO" type="Drug"><Normalization><mmtx cui="C0595301" phraseText="with AVAPRO" preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><entity charOffset="52:68" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.e.4" text="renal impairment" type="SPAN"><Normalization><mmtx cui="C0035078" phraseText="with renal impairment" preferredWord="Kidney Failure" semType="dsyn"/><mmtx cui="C0341697" phraseText="with renal impairment" preferredWord="Renal impairment" semType="dsyn"/></Normalization></entity><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.ddi.1"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.e.0"><relations><relation type="hasContext"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.e.4"/></relation><relation type="hasObject"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.e.2"/></relation></relations></interaction></drugInteraction><pair context="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.e.4" ddi="true" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.e.3" trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.68.e.0" type="Caution_Interaction"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.70" text="For male and female rats, 500 mg/kg/day provided an average systemic exposure to irbesartan (AUC0 24 hour, bound plus unbound) about 3 and 11 times, respectively, the average systemic exposure in humans receiving the maximum recommended dose (MRD) of 300 mg irbesartan/day, whereas 1000 mg/kg/day (administered to females only) provided an average systemic exposure about 21 times that reported for humans at the MRD. " type="negative"><entity charOffset="251:268" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.70.e.0" text="300 mg irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0986850" phraseText="the maximum recommended dose (MRD) of 300 mg irbesartan/day," preferredWord="irbesartan 300 MG" semType="clnd"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="81:91" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.70.e.1" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="an average systemic exposure to irbesartan" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.70.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.70.e.0"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.77" text="It is not known whether irbesartan is excreted in human milk, but irbesartan or some metabolite of irbesartan is secreted at low concentration in the milk of lactating rats. " type="negative"><entity charOffset="66:76" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.77.e.0" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="irbesartan" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><entity charOffset="158:167" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.77.e.1" text="lactating" type="Biomedical_Entity"><Normalization><mmtx cui="C0376261" phraseText="of lactating rats." preferredWord="Lactate" semType="phsu, orch"/><RxNorm RxCui="114202"/></Normalization></entity><entity charOffset="24:34" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.77.e.2" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="irbesartan" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><entity charOffset="99:109" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.77.e.3" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="some metabolite of irbesartan" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.77.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.77.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.77.e.2" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.77.e.1"/><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.77.e.3" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.77.e.1"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.83" text="Of 4925 subjects receiving AVAPRO (irbesartan) in controlled clinical studies of hypertension, 911 (18.5%) were 65 years and over, while 150 (3.0%) were 75 years and over. " type="negative"><entity charOffset="27:33" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.83.e.0" text="avapro" type="Biomedical_Entity"><Normalization><mmtx cui="C0595301" phraseText="AVAPRO" preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><entity charOffset="35:45" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.83.e.1" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="(irbesartan" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.83.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.83.e.1"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.87" text="AVAPRO may be administered with other antihypertensive agents and with or without food." type="negative"><entity charOffset="0:6" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.87.e.0" text="avapro" type="Biomedical_Entity"><Normalization><mmtx cui="C0595301" phraseText="AVAPRO" preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><entity charOffset="38:61" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.87.e.1" text="antihypertensive agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="administered with other antihypertensive agents" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.87.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.87.e.1"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.88" text="The recommended initial dose of AVAPRO (irbesartan) is 150 mg once daily. " type="negative"><entity charOffset="40:50" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.88.e.0" text="irbesartan" type="Biomedical_Entity"><Normalization><mmtx cui="C0288171" phraseText="(irbesartan" preferredWord="irbesartan" semType="phsu, orch"/><RxNorm RxCui="83818"/></Normalization></entity><entity charOffset="32:38" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.88.e.1" text="avapro" type="Biomedical_Entity"><Normalization><mmtx cui="C0595301" phraseText="The recommended initial dose of AVAPRO" preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.88.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.88.e.0"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.90" text="A low dose of a diuretic may be added, if blood pressure is not controlled by AVAPRO alone. " type="negative"><entity charOffset="16:24" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.90.e.0" text="diuretic" type="Biomedical_Entity"><Normalization><mmtx cui="C0012798" phraseText="A low dose of a diuretic" preferredWord="Diuretics" semType="phsu"/><RxNorm RxCui="3567"/></Normalization></entity><entity charOffset="78:84" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.90.e.1" text="avapro" type="Biomedical_Entity"><Normalization><mmtx cui="C0595301" phraseText="controlled by AVAPRO" preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.90.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.90.e.1"/></sentence><sentence biomedicalEntities="1" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.91" lineNumber="65" text="Hydrochlorothiazide has been shown to have an additive effect (see CLINICAL PHARMACOLOGY: Clinical Studies ). " type="irregular"><entity charOffset="0:19" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.91.e.0" text="Hydrochlorothiazide" type="Drug"><Normalization><mmtx cui="C0020261" phraseText="Hydrochlorothiazide" preferredWord="Hydrochlorothiazide" semType="phsu, orch"/><RxNorm RxCui="5487"/></Normalization></entity><entity charOffset="46:61" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.91.e.1" text="additive effect" type="Increase_Interaction"/><drugInteraction id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.91.ddi.1"><interaction trigger="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.91.e.1"><relations><relation type="hasObject"><ellipsisSentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.90" text="A low dose of a diuretic may be added, if blood pressure is not controlled by AVAPRO alone. "><entity charOffset="78:84" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.90.e.0" text="AVAPRO" type="Drug"><Normalization><mmtx cui="C0595301" phraseText="controlled by AVAPRO" preferredWord="Avapro" semType="phsu, orch"/></Normalization></entity></ellipsisSentence></relation><relation type="hasPrecipitant"><entity id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.91.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="labelDrug" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.91.e.0"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.95" text="There are no data on the clinical effects of lower doses of AVAPRO on diabetic nephropathy (see CLINICAL PHARMACOLOGY: Clinical Studies )." type="negative"><entity charOffset="10:17" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.95.e.0" text="no data" type="Biomedical_Entity"><Normalization><mmtx cui="C1572381" phraseText="no data on the clinical effects of lower doses of AVAPRO" preferredWord="No Data re: Ingredient" semType="phsu"/><RxNorm RxCui="53704"/></Normalization></entity><entity charOffset="60:66" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.95.e.1" text="avapro" type="Biomedical_Entity"><Normalization><mmtx cui="C0595301" phraseText="no data on the clinical effects of lower doses of AVAPRO" preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.95.e.0" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.95.e.1"/></sentence><sentence id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.96" text="A lower initial dose of AVAPRO (75 mg) is recommended in patients with depletion of intravascular volume or salt (eg, patients treated vigorously with diuretics or on hemodialysis) (see WARNINGS: Hypotension in Volume- or Salt-Depleted Patients )." type="negative"><entity charOffset="151:160" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.96.e.0" text="diuretics" type="Biomedical_Entity"><Normalization><mmtx cui="C0012798" phraseText="vigorously with diuretics" preferredWord="Diuretics" semType="phsu"/><RxNorm RxCui="3567"/></Normalization></entity><entity charOffset="24:30" id="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.96.e.1" text="avapro" type="Biomedical_Entity"><Normalization><mmtx cui="C0595301" phraseText="A lower initial dose of AVAPRO" preferredWord="Avapro" semType="phsu, orch"/><RxNorm RxCui="153668"/></Normalization></entity><pair ddi="false" e1="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.96.e.1" e2="Dailymed.7885b2a8-be4e-48ab-8113-4e6ab791eb98.s.96.e.0"/></sentence><positiveExamples number="17"/><negativeExamples number="95"/></document>